Your session is about to expire
← Back to Search
Chemotherapy + Radiation for Soft Tissue Sarcoma
Study Summary
This trial is testing the combination of pazopanib, chemotherapy, and radiation therapy or radiation therapy alone to treat patients with non-rhabdomyosarcoma soft tissue sarcomas.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- Group 1: Regimen A (pazopanib, chemoradiation)
- Group 2: Regimen C (pazopanib, radiation therapy)
- Group 3: Regimen B (chemoradiation)
- Group 4: Regimen D (radiation therapy)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Do we have any previous data to compare the results of this trial to?
"Clinical research for Radiation Therapy began in 1997. The first study was completed that year and was sponsored by Alfacell. After the Phase 3 approval was granted, following the first trial's completion, the number of active trials for this intervention has grown to 1099. They are being conducted across 74 different nations and in 2321 unique cities."
Are there different research hospitals testing this new treatment in town?
"This clinical trial is being hosted at Stanford Cancer Institute Palo Alto in Palo Alto, California, Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center in Denver, Colorado, and Saint Joseph's Hospital/Children's Hospital-Tampa in Tampa, Florida. 100 other locations are also participating."
What are the goals that this experiment seeks to achieve?
"The primary outcome of this study is to assess the feasibility of a pediatric dose of the medication. This will be evaluated over a 6-week induction period. Secondary outcomes include the percentage of patients who are local failure-free at 5 years following study entry, the percentage of patients who are regional failure-free at 5 years following study entry, and the percentage of patients who experience Grade 3 or higher toxicity as assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE)."
What are some of the most popular reasons people choose to go through Radiation Therapy?
"Radiation therapy is often used as a treatment for small cell lung cancer, but it can also ameliorate symptoms for patients with leukemia, myelocytic, acute, multiple sclerosis, lymphoma."
What does the research say about the effectiveness of Radiation Therapy?
"The first recorded study of radiation therapy was at Spectrum Health Hospital - Butterworth Campus in 1997. As of now, there have been a total of 1799 completed trials. Out of the 1099 ongoing studies, many are based in Palo Alto, California."
What is the target recruitment number for this research project?
"This specific study is no longer looking for participants, as it was first posted on 7/11/2014 and last updated on 10/18/2022. However, there are presently 2925 other trials involving pecomas and 1099 Radiation Therapy trials that are actively enrolling patients."
Who else is applying?
What portion of applicants met pre-screening criteria?
What state do they live in?
How many prior treatments have patients received?
What site did they apply to?
Share this study with friends
Copy Link
Messenger